BioLineRx (NASDAQ:BLRX – Get Free Report) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68, Zacks reports. BioLineRx had a negative net margin of 99.58% and a negative return on equity of 5.61%. The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million.
Here are the key takeaways from BioLineRx’s conference call:
- BioLineRx highlighted continued progress for GLIX1, including the start of its first-in-human Phase I/IIa trial in GBM and the first patient already dosed at NYU Langone. The company said additional sites at Northwestern and Moffitt will join the study soon.
- Management emphasized encouraging preclinical GLIX1 data, including dose-dependent tumor growth inhibition, survival benefit, and activity in temozolomide-resistant GBM models. They also noted a strong safety margin from tox studies and a rationale for combining GLIX1 with PARP inhibitors.
- The company expects to provide periodic GLIX1 clinical updates in the second half of 2026, with full dose-escalation results expected in 2027. The Phase IIa expansion is planned to explore additional cancers and combination regimens.
- APHEXDA royalties and sales improved, with Q1 2026 sales of $2.5 million versus $1.4 million a year ago, generating $0.5 million in royalty revenue for BioLineRx. Management said it views the uptick as evidence of stronger commercial momentum.
- BioLineRx’s cash and equivalents totaled $17.4 million at quarter-end, which it said should fund the current operating plan into the first half of 2027. The company also noted the pancreatic cancer trial’s interim futility readout remains expected later this year.
BioLineRx Price Performance
BioLineRx stock opened at $3.11 on Wednesday. The company has a current ratio of 1.95, a quick ratio of 1.78 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $2.60 and a 200 day moving average price of $2.88. BioLineRx has a 12-month low of $2.15 and a 12-month high of $7.77. The stock has a market cap of $13.51 million, a P/E ratio of -18.27 and a beta of 1.42.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on BioLineRx
About BioLineRx
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.
Read More
- Five stocks we like better than BioLineRx
- Quantum Computing’s Commercial Breakout Has Arrived
- Modine’s $4B AI Coup Freezes Out the Competition
- What Investors Need to Know About TSMC’s Hefty 17% Dividend Increase
- The SpaceX IPO Frenzy Is Creating 2 Very Different Bets
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
